Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IFRX 
InflaRx N.V. (IFRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: IFRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.07
1 Year Target Price $4.07
| 5 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -69.96% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 84.01M USD | Price to earnings Ratio - | 1Y Target Price 4.07 |
Price to earnings Ratio - | 1Y Target Price 4.07 | ||
Volume (30-day avg) 7 | Beta 1.46 | 52 Weeks Range 0.71 - 2.81 | Updated Date 11/5/2025 |
52 Weeks Range 0.71 - 2.81 | Updated Date 11/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.84 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date 2025-10-30 | When - | Estimate -0.158 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -35091.14% |
Management Effectiveness
Return on Assets (TTM) -39.42% | Return on Equity (TTM) -65.07% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 37879406 | Price to Sales(TTM) 515.92 |
Enterprise Value 37879406 | Price to Sales(TTM) 515.92 | ||
Enterprise Value to Revenue 198.27 | Enterprise Value to EBITDA 0.5 | Shares Outstanding 67747130 | Shares Floating 56940785 |
Shares Outstanding 67747130 | Shares Floating 56940785 | ||
Percent Insiders 6.38 | Percent Institutions 24.54 |
Upturn AI SWOT
InflaRx N.V.
Company Overview
History and Background
InflaRx N.V. is a biopharmaceutical company focused on discovering and developing novel anti-inflammatory therapeutics by targeting the complement system. Founded in 2007, it has focused on developing therapies for life-threatening inflammatory diseases. The company has made significant progress with its lead compound, vilobelimab.
Core Business Areas
- Drug Development: Focused on the discovery and development of novel therapeutics targeting the complement system, specifically C5a, to treat inflammatory diseases.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its drug candidates in various indications.
- Commercialization: Preparing for the commercialization of vilobelimab and other pipeline products, including manufacturing, sales, and distribution.
Leadership and Structure
The leadership team consists of experienced professionals in drug development, clinical research, and commercialization. The organizational structure includes departments for research and development, clinical operations, regulatory affairs, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- Vilobelimab: A first-in-class monoclonal anti-human complement factor C5a antibody. Its target indication is severe COVID-19. Revenue from this product is dependent on regulatory approvals and market uptake. Competitors include companies developing therapies for severe COVID-19 and other complement-targeted therapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. There is growing interest in complement-targeted therapies for various inflammatory and autoimmune diseases.
Positioning
InflaRx N.V. is positioned as an innovative player in the complement therapeutics space, with vilobelimab as its lead product candidate. Its competitive advantage lies in its specific C5a-targeting antibody technology.
Total Addressable Market (TAM)
The TAM for C5a-targeted therapies is significant, potentially reaching billions of dollars across various inflammatory and autoimmune diseases. InflaRx is positioning vilobelimab for unmet needs in severe COVID-19 and other critical care indications, capturing a portion of this TAM.
Upturn SWOT Analysis
Strengths
- Novel C5a-targeting technology
- Potential first-in-class therapy
- Experienced management team
Weaknesses
- Limited commercial infrastructure
- High R&D expenses
- Reliance on success of vilobelimab
Opportunities
- Expanding indications for vilobelimab
- Partnering with larger pharmaceutical companies
- Developing next-generation complement inhibitors
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- ALPN
- REGN
- LLY
- ABBV
Competitive Landscape
InflaRx N.V. faces competition from larger pharmaceutical companies with greater resources and established market presence. Its advantage lies in its novel C5a-targeting technology, but it needs to navigate regulatory hurdles and demonstrate clinical efficacy to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily measured by progress in clinical trials and financing activities.
Future Projections: Future growth is contingent on the successful commercialization of vilobelimab and expansion of the pipeline. Analyst estimates vary widely depending on regulatory and market outcomes.
Recent Initiatives: Recent initiatives include advancing vilobelimab through clinical trials, preparing for regulatory submissions, and exploring partnerships for commercialization.
Summary
InflaRx N.V. is a clinical-stage biopharmaceutical company with a novel C5a-targeting technology. Its success hinges on vilobelimab's clinical and regulatory outcomes. The company needs to navigate competition and secure partnerships for commercial success. Cash flow is negative and thus it requires additional funding to stay operational and achieve success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry databases
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About InflaRx N.V.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2017-11-08 | Co-Founder, CEO & Executive Director Dr. Niels C. Riedemann M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 74 | Website https://www.inflarx.de |
Full time employees 74 | Website https://www.inflarx.de | ||
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.